{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-019768","form_type":"8-K","ticker":"BCPC","cik":"0000009326","company_name":"BALCHEM CORP","filed_at":"2022-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.692639+00:00","generated_at":"2026-06-24T07:11:41.539076+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Balchem Q2 record net sales $236.7M (+17% YoY), GAAP EPS $0.92, adj. EPS $1.07","bullets":["Record net sales $236.7M, up 17% YoY; GAAP EPS $0.92, adjusted EPS $1.07 (record).","Adjusted EBITDA $56.5M, up 12.6% YoY; all three segments posted sales growth.","Completed acquisition of Kappa (vitamin K2 manufacturer) on June 21, 2022; expands nutrition portfolio.","Entered new $550M revolving credit facility due 2027, replacing $500M facility due 2023.","Cash from operations $48.2M; net debt $357.4M, leverage ratio 1.8x."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-019768","json":"https://secwatch.observer/filing/0001628280-22-019768.json","markdown":"https://secwatch.observer/filing/0001628280-22-019768.md","text":"https://secwatch.observer/filing/0001628280-22-019768.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/9326/000162828022019768/0001628280-22-019768-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/9326/000162828022019768/bcpc-20220729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T07:11:41.539076+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}